UNDERSTANDING COMPOUNDED SEMAGLUTIDE MAKING AN INFORMED DECISION
The usage of GLP-1 receptor agonists has grown worldwide. This class includes several different injectable medications, as well as an orally delivered drug. Many patients would prefer to avoid injections if possible, and there is an extremely low absorption of oral tablets (less than 1% per the labeling for RYBELSUS®).
For these reasons, prescribers and patients may prefer a patent-pending compounded formulation of Semaglutide for sublingual administration described here.
Pursuant to a prescription from a healthcare provider, this patent-pending compounded formulation is simple to prepare and has two ingredients: (1) RYBELSUS® tablets and (2) SubMagna™ HMW. It is important to note that this formula does not venture into the world where violations of molecular patents might occur such as what often may occur with compounded injectable medications.
The links below are being worked on and will house a great deal of information related to this patent-pending compounded formulation as well as white papers related to Semaglutide and GLP-1 receptor agonist medications in general.
If you would like to be able to provide a sublingually dosed Semaglutide, look no further than this patent-pending formulation.